Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 9, 2007, Pages 594-599

  Cyniak Magierska, A ^a   Brzezianska E ^a   Januszkiewicz Caulier, J ^a   Jarzab B ^b   Lewinski A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Papillary thyroid carcinoma; Point mutations; RAS oncogenes

Indexed keywords

K RAS PROTEIN; RAS PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CODON; DNA DETERMINATION; DNA SEQUENCE; EXON; FEMALE; FOLLICULAR CARCINOMA; GENE AMPLIFICATION; HUMAN; INCIDENCE; MALE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID PAPILLARY CARCINOMA;

EID: 35348872532     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981670     Document Type: Article

References (32)

1. Lewiński A, Ferenc T, Sporny S, Jarza̧b B. Thyroid carcinoma: diagnostic and therapeutic approach; genetic background. Endocr Regul 2000; 34: 99-113
2. Frattini M, Ferrario C, Bressan P, Balestra D, Cecco L De , Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004; 23: 7436-7440
3. Liu RT, Hou CY, You HL, Huang CC, Hock-Liew , Chou FF, Wang PW, Cheng JT. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 2004; 14: 616-621
4. Bouras M, Bertholn J, Detrieux-Berger N, Parvaz P, Paulin C, Revol A. Variability of H-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers. Eur J Endocrinol 1998; 139: 209-216
5. Vasko VV, Gaudart J, Allasia C, Savchenko V, Cristofaro J Di, Saji M, Ringel MD, Micco C De. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol 2004; 151: 779-786
6. Hara H, Fulton N, Yashiro T, Ito K, De Groot LJ, Kaplan EL. N-ras mutation: An independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994; 116: 1010-1016
7. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol 2003; 120: 71-77
8. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006; 30: 216-222
9. Cristofaro J Di, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, Micco C De. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 2006; 37: 824-830
10. th ed., John Wiley and Sons, Hoboken, New Jersey, 2002
11. Greene LF, Page DL, Fritz A, Batch M, Haller DG, Morrow M. AJCC Chapter 8: Thyroid. in: American Joint Committee on Cancer (AJCC) Cancer Staging Manual 6th ed., 2002. Springer, New York, 89-98
12. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A labolatory manual. Cold Spring Harbor Laboratory Press, 1989; 6: 22-34
13. Esapa C, Johnson S, Kendall-Taylor P, Lennard T, Harris P. Prevalence of ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 1995; 50: 529-535
14. Bartolone L, Vermiglio F, Finocchiaro M, Violi M, French D, Pontecorvi A, Trimarchi F, Benvenga S. Thyroid follicular oncogenesis in iodine-deficient and sufficient areas: search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene. J Endocrinol Invest 1998; 21: 680-687
15. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphism using the polymerase chain reaction. Genomics 1989; 5: 874-879
16. Karga H, Lee JK, Vickery Jr AL, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 1991; 73: 732-836
17. Salvatore D, Celetti A, Fabien N, Paulin C, Martelli ML, Battaglia C, Califano D, Monaco C, Viglietto G, Sanyoro M, Fusco A. Low frequency of p53 mutations in human thyroid tumors; p53 and ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol 1996; 134: 177-183
18. Fenton C, Anderson J, Lukes Y, Welch Dinauer CA, Tuttle RM, Francis GL. Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J Endocrinol Invest 1999; 22: 781-789
19. Suarez HG, Villard JA Du, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990; 5: 565-570
20. Challeton C, Bounacer A, Villard JA Du, Cailou B, Vathaire F De, Monier R, Schlumberger M, Suarez HG. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene 1995; 11: 601-603
21. Vasko V, Ferrand M, Cristofaro J, Carayon P, Henry JF, Micco C De. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 2745-2752
22. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Carcangiu ML, Costa J, Tallini G. RAS mutations are associated with aggressive tumor phenotype and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21: 3226-3235
23. Goretzki PE, Lyons J, Stacy-Phipps S, Rosenau W, Demeure M, Clark OH, Mac Cormick F, Röher HD, Bourne HR. Mutational activation of ras and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 1992; 16: 576-582
24. Lin SR, Tsai JH, Yang YC, Lee SC. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer 1998; 77: 1060-1065
25. ras. Oncogene 1992; 7: 475-480
26. Lin SR, Hsu CH, Tsai JH, Wang JY, Hsieh TJ, Wu CH. Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours. Br J Cancer 2000; 82: 1035-1040
27. Krohn K, Reske A, Ackermann F, Müller A, Paschke R. RAS mutations are rare in solitary cold and toxic thyroid nodules. Clin Endocrinol (Oxf) 2001; 55: 241-248
28. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003; 22: 6455-6457
29. Krohn K, Paschke R. BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules. Thyroid 2004; 14: 359-361
30. Brzeziańska E, Pastuszak-Lewandoska D, Migdalska-Sȩk M, Wojciechowska K, Lewiński A. Incidence assessment of BRAF V599E mutation in papillary thyroid carcinoma in the Polish population. (Abstract) Endokrynol Pol 2005; 56: 560-561
31. Brzeziańska E, Karbownik M, Migdalska-Sȩk M, Pastuszak-Lewandoska D, Włoch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res 2006; 599: 26-35
32. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457